Aerie Pharmaceuticals and DSM Biomedical Expand Collaboration Agreement

- August 1st, 2018

Aerie Pharmaceuticals (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, … Continued

Aerie Pharmaceuticals (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retina diseases and other diseases of the eye, and DSM Biomedical a global solutions provider in biomedical science and regenerative medicine, today reported that they have expanded their collaborative research, development, and license agreement.

As quoted in the press release:

In July 2017, Aerie announced that it had entered into a research collaboration and license option agreement with DSM for purposes of evaluating the sustained delivery of certain Aerie compounds using DSM’s bioerodible polyesteramide polymer technology. The initial focus has been on retinal diseases such as wet AMD (wet age-related macular degeneration) and DME (diabetic macular edema). Promising preclinical results have been obtained with polyesteramide-based implants containing AR-13503, an Aerie-owned preclinical small molecule, and Aerie expects to file an IND (Investigational New Drug) application in early 2019. AR-13503 inhibits Rho kinase and Protein kinase C and thus has the potential to address vascular dysfunction, fibrosis and inflammation in retinal diseases.

Click here to read the full press release.

Should you invest in the 2020 pharmaceutical market?

Read our FREE outlook report!
 

Leave a Reply